Influenza vaccine for Aboriginal and Torres Strait Islander people
The November meeting of the PBAC saw a positive endorsement for the extension of the influenza vaccine program for Aboriginal and Torres Strait Islander people aged 5 -17 years. This decision supports influenza vaccine funding for Aboriginal and Torres Straight Islander people of all ages on the NIP.
Please refer to the link below for further information:
November 2018 PBAC meeting positive recommendations
New vaccine preventable disease fact sheets
The Australian Institute of Health and Welfare (AIHW) has developed a series of factsheets detailing various vaccine preventable diseases (VPD's). These fact sheets provide information regarding the diseases, the number of cases reported in Australia, as well as rates of hospitalisation and deaths.
The fact sheets can be found via the following link:
Updated SAEFVIC Reporting Form (Online/ Print)
In support of the environment and sustainability efforts, MVEC encourages online reporting of adverse events following immunisations on www.aefican.org.au; online reporting ensures accuracy of information submitted to SAEFVIC.
However if a print copy is preferred, an updated SAEFVIC reporting form is now available on the 赛维克 页。
WHO Immunization Monitoring Academy Webinars
The World Health Organization (WHO) is currently hosting a series of webinars exploring specific topics in immunisation monitoring. These webinars are open to anyone with an interest in this area. Further information and details on registration can be found via the link below:
Immunization Monitoring Academy: Webinars
New meningococcal resources
这 澳大利亚科学院 has released a new video detailing the devastating impact of meningococcal disease.
To access this video, as well as other meningococcal information, please follow the link below:
Menactra® 和 Prevenar 13® 共同给药
Menactra® should not be administered on the same day as Prevenar 13®. Studies have shown that co-administration may result in a decreased immune response to some of the pneumococcal serotypes. If both vaccines are required, Prevenar 13® should be administered first followed by Menactra® at least 4 weeks later. If these vaccines are inadvertently administered on the same day, Prevenar 13® should be repeated a minimum of 8 weeks later. Menveo® and Nimenrix® may be co-administered with Prevenar 13®.
For further information please refer to The Australian Immunisation Handbook
World Health Organisation- Rabies
The World Health Organisation (WHO) has updated its position on rabies immunisation for pre- and post-exposure prophylaxis. The following position paper provides a summary on rabies disease and vaccines and concludes with the current WHO position on the use of rabies vaccines worldwide. The systematic review can also be accessed below. For further information on rabies disease please refer to MVEC's reference page.
Rabies vaccines: WHO position paper - April 2018
Pre-exposure rabies prophylaxis: a systematic review
Global Vaccine Safety
The Global Vaccine Safety Initiative was set up in 2011 by the World Health Organsiation (WHO) to ensure that all countries had strategies in place to ensure vaccine safety. The latest highlight is available via the following link and has some great information on Adverse Events Following Immunisation (AEFI) training in our region (WPRO).
英联邦资助的青少年脑膜炎球菌 ACWY 疫苗
从 2019 年 4 月开始，国家免疫计划 (NIP) 将资助 15-19 岁青少年接种脑膜炎球菌 ACWY 疫苗。在 2017 年和 2018 年，维多利亚州的青少年接种了脑膜炎球菌 ACWY 疫苗 (Menactra®)，作为州资助计划的学校计划的一部分。 NIP 的这一变化将确保全国的青少年能够获得疾病保护。详情请参阅以下卫生部长的公告：
国会议员 Greg Hunt 宣布：$52 百万为青少年免费提供脑膜炎球菌疫苗
The Australian Immunisation Handbook-online edition
The newest update of The Australian Immunisation Handbook has arrived! It is now an online version ensuring that up to date information is accessible for all, in a format that is easy to navigate. To access the new handbook please follow the link below:
The Australian Immunisation Handbook